SCHEMBL2232772

SCHEMBL2232772

N#[N+]c1ccccc1CCN

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 11/20 0.50
HTR2A P28223 5/20 0.45
HRH1 P35367 2/20 0.41
CYP2A6 P11509 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
ADRA2C P18825 1/20 0.38
MPO P05164 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
NFKB1 P19838 1/20 0.37
HTR1D P28221 1/20 0.37
HTR1B P28222 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
CTSK P43235 1/20 0.37
HTR6 P50406 1/20 0.37
CYP2A13 Q16696 1/20 0.37
PMP22 Q01453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570756 0.82 PNMT (0.44) TAAR1HTR2ACYP2A6LOXL2CYP1A2
SCHEMBL1583827 0.78 CYP4F2 (0.33) ADRA2C
SCHEMBL5084643 0.78 TDP1 (0.39) TAAR1
SCHEMBL224549 0.75 TAAR1 (0.70) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2
SCHEMBL6409297 0.74 LIPG (0.50)
SCHEMBL13824617 0.73 MGLL (0.47) SMN1; SMN2CYP2D6
SCHEMBL17718234 0.73 APOBEC3G (0.43) CYP2A6CYP1A2
SCHEMBL5573340 0.70 LIPG (0.39) CYP3A4CYP2D6
SCHEMBL5551583 0.69 CYP2A6 (0.31) CYP2A6
SCHEMBL6314758 0.69 HTR2A (0.74) TAAR1HTR2AHRH1CYP2A6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2351128-B1 NOVEL MATERIALS AND THEIR USE FOR THE ELECTROCATALYTIC EVOLUTION OR UPTAKE OF H2 COMMISSARIAT ENERGIE ATOMIQUE (FR) 2020-03-04 EP disclosed
US-8895207-B2 Materials and their use for the electrocatalytic evolution or uptake of H2 COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-11-25 US disclosed
US-20110294044-A1 Novel Materials and Their Use for the Electrocatalytic Evolution or Uptake of H2 COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2011-12-01 US disclosed
EP-2351128-A1 NOVEL MATERIALS AND THEIR USE FOR THE ELECTROCATALYTIC EVOLUTION OR UPTAKE OF H2 Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2011-08-03 EP disclosed
WO-2010046774-A1 NOVEL MATERIALS AND THEIR USE FOR THE ELECTROCATALYTIC EVOLUTION OR UPTAKE OF H2 COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-04-29 WO disclosed
EP-2180539-A1 Novel materials and their use for the electrocatalytic evolution or uptake of H2 Commissariat à l'Energie Atomique (FR) 2010-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294044-A1 Novel Materials and Their Use for the Electrocatalytic Evolution or Uptake of H2 FECH, EPCAM, PPOX TAAR1 3422/4885HTR2A 1872/4885HRH1 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.